Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations by Daniela A. Herzig et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSYCHIATRY
ORIGINAL RESEARCH ARTICLE
published: 29 September 2014
doi: 10.3389/fpsyt.2014.00133
Alcohol and relatively pure cannabis use, but not
schizotypy, are associated with cognitive attenuations
Daniela A. Herzig1,2,3*, David J. Nutt 4 and Christine Mohr 1,5
1 Department of Experimental Psychology, University of Bristol, Bristol, UK
2 Institute for Response-Genetics, University of Zurich, Kilchberg, Switzerland
3 Clienia AG Littenheid, Littenheid, Switzerland
4 Neuropsychopharmacology Unit, Imperial College London, London, UK
5 Faculté des Sciences Sociales et Politiques, Institut de Psychologie, Université de Lausanne, Lausanne, Switzerland
Edited by:
Caroline Gurvich, Monash University,
Australia
Reviewed by:
John Gigg, University of Manchester,
UK
Bernhard J. Mitterauer,
Volitronics-Institute for Basic
Research Psychopathology and Brain
Philosophy, Austria
*Correspondence:
Daniela A. Herzig, Clienia AG
Littenheid, Littenheid, Switzerland
e-mail: daniela.herzig@clienia.ch
Elevated schizotypy relates to similar cognitive attenuations as seen in psychosis and
cannabis/polydrug use. Also, in schizotypal populations cannabis and polydrug (including
licit drug) use are enhanced.These cognitive attenuations may therefore either be a behav-
ioral marker of psychotic (-like) symptoms or the consequence of enhanced drug use in
schizotypal populations.To elucidate this, we investigated the link between cognitive atten-
uation and cannabis use in largely pure cannabis users (35) and non-using controls (48),
accounting for the potential additional influence of both schizotypy and licit drug use (alco-
hol, nicotine). Cognitive attenuations commonly seen in psychosis were associated with
cannabis and alcohol use, but not schizotypy. Future studies should therefore consider
(i) non-excessive licit substance use (e.g., alcohol) in studies investigating the effect of
cannabis use on cognition and (ii) both enhanced illicit and licit substance use in studies
investigating cognition in schizotypal populations.
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INTRODUCTION
Cannabis sativa (marijuana) is currently the most widely used ille-
gal substance in Europe (1). Past year cannabis use was reported
by about 11.2% of all 15–34 year olds (1). This elevated preva-
lence rate (when compared to other illicit drug use) is concerning,
because cannabis use might go along with both cognitive attenu-
ation (2, 3) and mental health problems, in particular psychosis
(4–9). Yet, only a minority of cannabis users (CU) will develop psy-
chotic illnesses (5–7, 10). Therefore, other factors likely influence
adverse consequences associated with cannabis use (9, 11).
Here, we focused on the supposedly negative implications of
cannabis use on cognitive functioning while accounting for indi-
viduals’ schizotypy and associated licit drug use. We did so based
on the following reasoning. On the one hand, relatively pure CU
(i.e., no regular drug use other than marihuana, cigarettes, or
alcohol) have attenuated cognitive functioning compared to non-
users (3), e.g., in verbal working memory (12), verbal short-term
memory (13), and mental flexibility (3, 14). On the other hand,
as detailed below, schizotypal personality features are not only
part of the psychosis dimension but also associate with cognitive
attenuations, cannabis use, as well as licit drug use.
The schizotypy approach assumes that psychotic symptoms
exist along a continuum, with severest symptoms occurring in
schizophrenia and mild sub-clinical ones in schizotypal indi-
viduals from the general population (15). Schizotypy is com-
monly assessed using self-report questionnaires (16, 17). Scores
on these questionnaires can be commonly divided into symptom
dimensions known from patients, e.g., consisting of positive
schizotypy (e.g., magical thinking, unusual experiences), negative
schizotypy (e.g., anhedonia), and cognitive disorganization [e.g.,
odd speech and behavior; (16, 18)]. When it comes to laboratory
measures, high as compared to low schizotypes yield relatively
impaired cognitive performance, e.g., in working memory (19,
20), cognitive flexibility (21), and verbal short-term memory (22,
23). Most relevant to our reasoning, high schizotypy goes along
with elevated substance use of, e.g., cannabis (24–28), nicotine, and
alcohol (26, 29). Similarly, an elevated drug use has been reported
in schizophrenia when compared to healthy controls (2, 6, 30–34).
Given the above described interrelationships, it is possible that
the link between cannabis and cognition is influenced by indi-
viduals’ schizotypal features and/or additional licit drug use. The
latter reasoning is particularly likely given that CU show higher
consumption of nicotine and/or alcohol when compared to non-
users (35, 36). Studies that assessed all three variables (cognition,
cannabis use, and schizotypy) found that CU showed both worse
cognitive performance and higher schizotypy scores (24, 37), and
that only in CU schizotypal symptoms correlated with worse cog-
nitive performance (37). When it comes to licit drug use, the
available information is even scarcer, as these studies did not
report on a potential effect of licit (nicotine, alcohol) drug use (24,
37). We therefore investigated the link between cognitive attenua-
tion and cannabis use in largely pure CU and non-cannabis users
(nCU), accounting for the potential additional influence of both
schizotypy and licit drug use (alcohol, nicotine).
We expected that both illicit and licit drug use might be
more important than schizotypy to explain variance in cognitive
performance (38–40). If schizotypy would additionally or instead
explain variance in cognitive performance, we would expect
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the cognitive disorganization dimension (25–27) and/or positive
schizotypy dimension (24,41,42) to be more relevant than the neg-
ative schizotypy dimension (27, 37, 42–44) that frequently resulted
in heterogeneous findings.
MATERIALS AND METHODS
PARTICIPANTS
We recruited participants via advertisements looking for both pure
CU (see also screening section) and non-nicotine consuming nCU.
Advertisements were distributed at the local University and its
vicinity on paper and electronically. We also used a local web-
site (“Gumtree”). We recruited 83 healthy native English-speaking
participants [35 CU (23 males) and 48 nCU (20 males)]. Partici-
pants either received monetary compensation for travel expenses
or course credits. The University of Bristol ethics committee
approved this study. All participants provided written informed
consent prior participation.
SCREENING
In both groups (CU, nCU), people were excluded if they reported
excessive alcohol use (>50 units of alcohol/week for men, >35
units of alcohol/women), alcohol use within 12 h prior to test-
ing, a neurological, psychological, or psychiatric history, or visual
problems (including dyslexia). Prior to study inclusion, partici-
pants were alerted that we would ask for a urine sample for drug
screening. We then asked about illegal substance use within the
past 3 months. To encourage honest responding, volunteers were
kept unaware of the drug spectrum assessed with the urine test
(it detected cannabis metabolites until about 2 weeks after its con-
sumption). To ensure recruitment of largely pure CU, participants
were excluded if they indicated regular illicit drug use (apart from
cannabis) in the past 3 months (more than twice) and/or use
within 2 weeks prior testing. Participants were also asked about
their cannabis and nicotine use habits (e.g., average amount of
times cannabis used/cigarettes per week) in the past 30 days prior
testing. Data with a negative drug test were not excluded if CU
self-reported occasional use (on average 1–2 times/week within the
past 30 days), and/or indicated regular or frequent use (on aver-
age >2 times/week in the past 30 days), but not within the past
2 weeks (45). If regular or frequent CU indicated use within the
past 2 weeks, participants with a negative drug test were excluded
from further analysis. The healthy nCU were excluded if they
reported nicotine and cannabis use in the past 30 days, and if they
showed a positive drug test.
PROCEDURE
Participants were firstly screened by means of the procedure out-
lined above. Subsequently, participants came to the local depart-
ment for a 1 h testing session. The CU were asked to abstain prior
testing from (i) cannabis use at least 2 h and (ii) nicotine use
30 min. We chose this abstinence period for cannabis, because gen-
eral psychotropic effects seem to taper off 2–3 h post-consumption
(46). In the case of nicotine, acute effects on cognition seem
observable within 15–35 min of nicotine consumption [e.g., Ref.
(47, 48)]. After having provided written informed consent, par-
ticipants underwent the urine test before continuing to the test-
ing session. Participants first completed the drug and schizotypy
questionnaires, before performing the cognitive tasks. Partici-
pants performed the tasks outlined below as well as a handedness
questionnaire and a lateralized lexical decision task. Results from
the latter will be presented elsewhere. Task order was random-
ized between participants. Finally, participants were debriefed and
reimbursed for their time.
QUESTIONNAIRES
Schizotypy
The Oxford-Liverpool Inventory of Feelings and Experiences (17,
49) is a 159-item self-report instrument consisting of the follow-
ing sub-scales: positive schizotypy (unusual experiences=UnEx,
30 items), negative schizotypy (Introvertive Anhedonia= IntAn,
27 items), and cognitive disorganization (=CogDis, 24 items).
Finally, 23 items assess impulsive non-conformity (ImpNC). Nor-
mative values can be found in Mason et al. (17, 49). We did not
account for IntAn and ImpNC in this study, because of the het-
erogeneity in findings in the former case (see Introduction) and
because ImpNC does not represent a schizotypy dimension (17).
Drug questions
Participants reported on their prior drug use (lifetime, past year,
and past month drug use), e.g., their alcohol, cigarette, cannabis,
cocaine, amphetamine, hallucinogen, opiate, and prescribed drug
use. Items were taken from the national household survey on drug
abuse (50). This questionnaire taps into seven DSM-IV criteria for
drug dependence (past 12 months) by asking if people (1) spent
a lot of time obtaining, using, or recovering from the drug, (2)
experienced a marked increase in amount and frequency of drug
use, (3) experienced a marked decrease in the drug effect, and (4)
gave up or reduced important social, occupational, or recreational
activities due to drug use. It also asks if people experienced (5)
drug-induced psychological problems (such as depressive mood),
(6) drug-induced physical problems, and (7) a persistent desire
for the drug or unsuccessful attempts to stop drug use. For each
positive answer, participants received 1 point (maximum score 7)
with higher values indicating higher substance use severity. Par-
ticipants also indicated the average amount of joints/cigarettes
per week they used within the past 30 days. For this reason, it
is possible that current non-smokers (no tobacco use within the
past month) receive a nicotine severity score 6= 0 if they have
smoked within the past 12 months (this only concerned 2 of the
48 non-smokers).
BEHAVIORAL MEASURES: COGNITIVE FUNCTIONING
Trail making task
The trail making task (TMT) assessed executive functioning (51,
52). In the TMT A, participants connected numbered circles in
chronological order (1–25) by drawing a line, as fast as possi-
ble. In the subsequent TMT B, participants saw circles containing
numbers or letters. They drew a line as quickly as possible in
chronological order switching between numbers and letters, i.e.,
from 1 to A, from A to 2, from 2 to B, etc. The RT for both versions
was recorded. The TMT-index (RT version B minus version A)
was used as an estimate of cognitive flexibility (53). Norm values
are available from Tombaugh (54).
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Verbal short-term memory (story-recall/logical memory)
We used a subtest of the revised version of the Wechsler adult intel-
ligence scale (55). The experimenter read out a 60 words story. The
participant was asked immediately afterwards to recall as many
details as possible (maximum of 23 possible points). Normative
data for young adults and university samples can be found in
Bowden et al. (56) and Ivison (57), respectively.
Verbal working memory (two-back task)
Comparable to previous reports (58, 59), participants saw 64
sequentially presented digits (ranging from 1 to 9) in the middle
of the computer screen (white on black background, font Arial,
size 16). Participants had to press a given response key when the
current digit (n) was identical to the digit n-2 (target trials). In
all non-target trials, participants had to press another response
key. Response key allocation was counterbalanced between par-
ticipants. A third of the trials (n= 20) were target trials, and
the remaining trials were non-target trials [n= 44; e.g., 59]. To
increase task difficulty, we added intrusion trials. These were
included to prevent restarting memorization after each successful
target identification. Consequently, targets could occur twice in a
row. Each stimulus appeared for 2000 ms, with an inter-stimulus
interval of 500 ms (60) before the next digit appeared. Participants
had to respond within 2500 ms, otherwise the trial was counted
as an omission. All participants performed 16 practice trials. We
measured the percentage of the correctly identified targets, as well
as mean RTs for correct trials (59, 61).
As an additional note, we also measured a computerized Go
NoGo task. Due to an overall ceiling performance, we omitted this
task from further analysis.
DATA ANALYSIS
To determine if cannabis use affects cognitive functioning, we
conducted separate univariate ANOVAs with group (CU, nCU)
as between-subjects factor on the following measures: percent-
age of correct responses [(number of correctly identified target
stimuli× 100)/total of targets] and RT in the two-back task, TMT-
index, and the percentage of correctly identified units in the story-
recall task [(number of correctly identified units× 100)/total of
units)].
To determine effects of drug use and schizotypy on cognition,
we firstly investigated the demographic characteristics of our pop-
ulation. We found sex differences between drug groups (see Results
for details). We then correlated all variables with the outcome mea-
sures to preselect variables for the regression model (see Results for
details). Neither age nor schizotypy significantly correlated with
the cognitive measures. Due to the previous literature (see Intro-
duction), we nevertheless kept UnEx scores and CogDis scores
for the hierarchical regressions as follows: sex was entered in the
first step, schizotypy (UnEx scores, CogDis scores) in the second
step, and drug use severity (nicotine, alcohol, and cannabis) in the
third step. Severity was preferred over frequency due to the former
measure’s relevance to clinical addiction. Exploratory analysis con-
firmed that drug use severity was more important than drug use
frequency in the current regression analyses. Thus, three blocks
of predictors were entered in nested blocks, meaning that each
subsequent block contained all prior predictors and the additional
predictors from the current block. Presentation of results only
includes the new predictors entered, for economy of presentation.
All tolerance values were above 0.2 (62) and all independent vari-
ables were mean-centered. Thus, multi-collinearity between the
independent variables was considered negligible. The dependent
variables were (i) percentage correctly identified targets and mean
RT for correctly identified targets and non-targets in the two-back
task; (ii) TMT-index; and (iii) percentage of correctly recalled units
in the story-recall task.
Kolmogorov–Smirnov tests for the groups separately revealed
normal distribution for all behavioral measures. All p-values were
two-tailed and the α-level was set at 0.05.
RESULTS
PARTICIPANTS
We identified 35 CU (out of 83 healthy native English-speakers).
On average (±SD), CU smoked 11.14 joints per week (±12.16), a
frequency that can be classified as heavy use [>5 joints per week;
(63)]. The last cannabis consumption was on average more than
24 h ago (114.37± 143.02 h) with 4 CU reporting cannabis use 2–
6 h before testing. When only individuals are considered whose last
cannabis consumption was more than 6 h ago, the results stayed
largely the same. Age of cannabis use onset was at 15.46 years of age
(±1.87 years). Within the CU group, 13 individuals were educated
to college level (37%), 1 to secondary school (3%), and 21 to uni-
versity degrees (60%). Of the 48 nCU, 12 individuals had college
degrees (25%) and 36 had university degrees (75%). A chi-square
test indicated that the two groups did not differ from each other
in terms of highest finished education level [χ2(df= 2)= 3.03,
p= 0.22]. A chi-square test on sex distributions showed that sig-
nificantly more males (n= 23) were in the CU group as compared
to the nCU group [n= 20; χ2(df= 1)= 4.69, p= 0.03].
We also compared schizotypy sub-scale scores to a previous
normative sample (17) via calculations of Cohen’s d (64) with val-
ues of ±0.2/±0.5/±0.8 being indicative of a small/medium/large
effect size, respectively. As can be seen from Table 1, schizotypy val-
ues were largely comparable to normative data, as no large effect
sizes were found. A medium effect size was indicated for UnEx,
with higher values in the normative sample as compared to the
current sample (see Table 1).
As can be seen from Table 2, the groups (CU, nCU) were com-
parable in age. However, CU as compared to nCU scored higher
on UnEx (as a trend), nicotine, cannabis, and alcohol use severity
Table 1 | Means, SDs, and effect sizes (Cohen’s d ), comparing the
values of the normative sample with the current sample.
Questionnaire Norm values Current sample Cohen’s d
(N =508) (N =83)
Mean SD Mean SD
O-LIFE: UnExa 9.70 6.70 6.36 4.92 0.52
O-LIFE: CogDisb 11.60 5.80 10.61 5.28 0.17
aUnusual experiences.
bCognitive disorganization.
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(since nCU were screened for weekly cannabis and cigarette use,
the comparisons between nCU and CU were not conducted for
these variables).
COGNITIVE FUNCTIONING
Group comparisons
The separate univariate ANOVAs on the outcome measures
revealed that CU performed significantly worse in the story-recall
task, and slightly worse on the working memory task as compared
to nCU (Table 3). The results for the remaining outcome variables
were not significant (Table 3).
Regression analyses
The initial correlation analyses between task performances, schizo-
typy sub-scale scores, age, and drug measures revealed that neither
age nor schizotypy related to cognitive functioning (all p-values
>0.10, see Table 4). Accordingly, age was not further considered.
Table 2 | Age, schizotypy, and drug use statistics comparing CU and
nCU.
Variables CUc (N=35) nCUd (N=48) t p
Mean SD Mean SD
Age 22.51 5.63 21.67 3.56 0.84 0.40
UnExa 7.63 6.04 5.44 3.71 1.90 0.06
CogDisb 10.46 5.75 10.73 4.97 −0.23 0.82
Cigarettes/week 24.66 28.67 n/a n/a n/a n/a
Joints/week 11.14 12.16 n/a n/a n/a n/a
Nicotine use severity 1.94 1.86 0.08 0.45 5.78 0.00
Cannabis use severity 2.97 1.95 0.00 0.00 9.03 0.00
Alcohol use severity 2.29 1.84 1.31 1.42 2.72 0.01
aUnusual experiences.
bCognitive disorganization.
cCannabis users.
dCannabis non-users.
Values were compared between groups (CU, nCU) using independent t-tests
(statistical results are shown in this table; t-values, df=81, p-values). Significant
group differences are highlighted in bold, trends in gray.
UnEx and CogDis on the other hand were included as a priori
predictions were formulated based on the published literature (see
Introduction and Data Analysis).
The significant results from the subsequent regression analy-
ses (see Data Analysis for further details) can be seen in Table 5.
With regard to the control variables, we found that sex predicted
verbal short-term memory. Post hoc independent t -tests revealed
that women were significantly better than men in the story-
recall task [women: 66.63± 12.08%, men: m= 58.54± 15.39%;
t (81)= 2.65, p= 0.01]. Entering schizotypy in the second step
explained no additional variance on top of sex (see Table 5).
Drug use severity in the third step predicted significant amounts
of variance in the outcome measures. Here, higher alcohol use
severity predicted lower working memory performance, and
higher cannabis use severity predicted reduced verbal short-term
memory on top of sex and schizotypy (Table 5).
DISCUSSION
We investigated whether pure cannabis use hampers cognitive per-
formance, or whether cognitive attenuation is also, or even better
explained by associated licit drug use and psychotic-like features
(schizotypy). For this purpose, we tested cognitive functions com-
monly associated with drug use and schizotypy in CU and nCU.
The main findings were that (i) CU as compared to nCU per-
formed worse on story recall and slightly worse on the two-back
task, but not on the TMT, (ii) CU scored higher than nCU on
positive schizotypy (as a trend), and drug use other than cannabis,
(iii) regression analyses showed that enhanced cannabis use pre-
dicted decreased verbal short-term memory, whereas enhanced
alcohol use predicted reduced working memory performance, (iv)
none of the schizotypy sub-scales explained any additional vari-
ance in cognitive functioning. The implications of these findings
are discussed below.
ROLE OF CANNABIS USE SEVERITY
Our results showed that CU performed worse than nCU on tasks
measuring verbal short-term memory (story recall), and higher
cannabis use severity was associated with worse performance in
this task. Our results also showed that these relatively negative
cognitive implications were not associated with individuals’ self-
reported schizotypy. The observation that worse story recall is
Table 3 | Descriptive and statistical values for the cognitive measures, comparing performance of CU and nCU.
Variables CUb (N=35) nCUc (N=48) F (1,81) p Partial η2
Mean SD Mean SD
Two-back % target correct 86.00 13.49 90.52 8.07 3.62 0.06 0.04
Two-back mean RT 822.57 164.00 821.42 205.92 0.00 0.98 <0.01
TMTa index 23.77 13.58 23.56 16.58 0.00 0.95 <0.01
Story-recall % correct 55.90 14.78 67.21 12.19 14.55 <0.01 0.15
aTrail making task.
bCannabis users.
cCannabis non-users.
Values were compared with univariate ANOVAs, and significant values are highlighted in bold, trends in gray.
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associated with cannabis use is in line with previous studies (3, 13,
46). However, story recall (verbal memory) was the only task that
was affected by cannabis use, whereas relatively impaired perfor-
mance on another cognitive task (working memory as assessed
with the two-back task) was related to enhanced alcohol use
instead. Previous studies have indicated that cannabis use has a
negative impact on working memory performance (46, 65) and
mental flexibility (3, 66) as well. Our findings suggest that these
previous findings on cannabis use were potentially confounded by
concomitant non-excessive alcohol use (3, 67).
Despite some evidence that cannabis use is still associated with
cognitive impairments after adjusting for alcohol use (68), inde-
pendent studies (8, 36) report that CU tend to consume higher
amounts of other drugs as well. This additional drug use, as
frequently not assessed, might lead to misleading conclusions
Table 4 | Correlations between potential predictor variables and
cognitive measures.
Variables Two-back task
% target correct
Two-back task
mean RT
TMTc
index
Story-recall
% correct
Age −0.06 −0.16 −0.08 −0.03
UnExa −0.08 0.06 0.08 −0.03
CogDisb 0.02 −0.01 −0.04 −0.07
Nicotine
use severity
−0.24* 0.08 0.04 −0.41***
Cannabis
use severity
−0.27* 0.14 0.10 −0.47***
Alcohol use
severity
−0.29** 0.40*** 0.28** −0.07
aUnusual experiences.
bCognitive disorganization.
cTrail making task.
*Significant at p≤0.05.
**Significant at p≤0.01.
***Significant at p≤0.001.
Significant values are highlighted in bold.
about cannabis effects on cognition. Particularly licit drug use like
alcohol seems to be a relevant confounding factor. For instance,
whereas in some studies alcohol use is either statistically controlled
for (63) or subjects with alcohol abuse are excluded from partici-
pating (13, 14), other studies do not account for this variable (24,
69, 70, 71). Moreover, alcohol and cannabis are thought to exert
comparable effects on cognition, i.e., cognitive attenuation in ver-
bal memory (72–74), cognitive flexibility (75, 76), and working
memory (77–79). Future studies should consider (non-excessive)
licit drug use as a potential confounding factor when investigating
the effects of cannabis use on cognition.
ROLE OF SCHIZOTYPY
Of additional significance was the observation that schizotypy did
not explain variance in most cognitive tasks. We do not think
that this finding can be explained by deviant features of our sam-
ple, because we replicated many previous observations, i.e., that
CU as compared to nCU scored slightly higher on measures of
positive schizotypy (24, 27, 28, 41, 42, 44). The observation that
schizotypy was not importantly related to cognitive functioning
would indicate that the impairments in, e.g., working memory
(19, 20), cognitive flexibility (21), and verbal memory (22, 23)
may be influenced by individuals’ concomitant drug use.
Unfortunately, the above mentioned studies did not report on
drug use (19, 21–23, 80), or only screened for substance use his-
tory without specifying the substances controlled for (20, 81). It is
thus possible that substances (e.g., illicit as well as licit) influ-
enced the relationship between schizotypal symptoms and the
cognitive functions assessed in these experiments (38–40). In par-
ticular, our results suggest that cannabis may be more relevant
than schizotypy for cognitive attenuations in verbal short-term
memory, and alcohol may be more relevant than schizotypy for
cognitive attenuations in working memory (82).
The specific cannabis effects on story recall, but not on the
two-back or TMT may also suggest that not all cognitive functions
are equally sensitive to cannabis-related attenuations. Even though
many studies observe CU to show impairments compared to nCU
on tasks measuring working memory (46) and mental flexibility
(3, 66), this may not always be the case (71, 83). In fact, different
Table 5 | Significant results (including trends in gray) from the regression analyses assessing the effect of sex (step 1), schizotypy (UnExa,
CogDisb; step 2), and drug use severity (nicotine, alcohol, and cannabis; step 3) on cognitive measures.
Outcome variables Step Significant predictor β-value Total R2 ∆R2 F for ∆R2
Two-back % target correct 3 Alcohol −0.25* 0.15** 0.14** 4.25**
Two-back mean RT 1 Sex −0.21† 0.04† 0.04† 3.61†
3 Alcohol 0.39*** 0.18** 0.13** 4.03**
Story-recall % correct 1 Sex 0.28** 0.08** 0.08** 7.02**
3 Cannabis −0.41** 0.30*** 0.21*** 7.46***
† p≤0.10.
*Significant at p≤0.05.
**Significant at p≤0.01.
***Significant at p≤0.001.
aUnusual experiences.
bCognitive disorganization.
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meta-analyses draw inconsistent conclusions about which cogni-
tive functions qualify as cognitive markers, or endophenotypes for
pathological changes. Findings are inconsistent in CU and along
the schizophrenia spectrum, with some studies pointing to ver-
bal memory impairments in both populations (65, 84–86), some
pointing to cognitive flexibility impairments (86, 87), and oth-
ers reporting consistent working memory impairments in both
patients with psychosis and CU (65, 85, 86). Alternatively, higher
THC-content of used cannabis may relate to more prominent cog-
nitive attenuations (88). Therefore, future studies should report
the type and/or strength of cannabis used to improve reliability of
findings.
Admittedly, all these complex functions tap into a variety of
cognitive sub-functions. For this reason, to increase reliability of
findings across studies and populations, the research community
might consider behavioral markers that are less complex in their
cognitive demands (89–92). Additionally, the pathophysiology of
psychotic disorders is currently unknown, and the disorders are
quite heterogeneous in their phenotypic expression. Consequently,
we may increase the reliability of findings by accounting for seem-
ingly related as well as unrelated factors potentially influencing
the relationship between cannabis, cognition, and psychosis (-
risk). For instance, studies could consider different yet potentially
equally relevant personality traits such as those tapping on the
autism spectrum (93) or the bipolar spectrum (94, 95). Beyond
personality, studies could consider genetic predisposition (96), IQ
(97), and neurochemical peculiarities such as dopamine receptor
availability (98, 99) that may influence the effect cannabis exerts
on cognition. Such factors are also relevant for the link between
psychosis and drug use, e.g., genetic predisposition (100, 101),
IQ (102–104), and neurochemical peculiarities (99). At present, it
is impossible to account for all putatively influential variables,
and hence additional studies need to be conducted to repli-
cate our and similar findings, be it clinical, experimental, and/or
epidemiological studies.
STUDY LIMITATIONS AND FUTURE RESEARCH
In the catchment area of our study, the “binge drinking culture”
reflects on the high acceptance for alcohol use (105). Consequently,
we refrained from pre-selecting participants according to their
alcohol use, as the recruitment of pure CU (rather than polydrug
users) turned out to be challenging, and was not facilitated by the
modest incentives we could offer. Likewise, controlling for the co-
use of nicotine seemed even more unavoidable, because cannabis
is mostly used in combination with nicotine (106). Yet, controlling
for nicotine could have been relevant, because nicotine itself might
counteract the effects of cannabis on cognition (33, 107–109). We
therefore suggest that future studies should elucidate the role of
nicotine and cannabis more directly.
The gender composition differed between groups, a difference
common to studies such as the current one. This gender differ-
ence could have also affected the group differences in story recall.
Typically, females perform better on verbal short-term memory
tasks than males (110), a finding also observed here. Since the nCU
group consisted of more females than the CU, this group difference
could alternatively explain the worse story recall in CU. How-
ever, since cannabis use related to worse story-recall performance
on top of sex in the regression analysis, we deem it unlikely that
the group differences are solely due to effects associated with the
unequal sex distribution. Nevertheless, future studies on drug use
and cognition should aim to control for sex differences.
A final, frequently mentioned study limitation is the sample
size, also relevant to the conducted analyses. For regression analy-
ses, the guidelines for recommended sample sizes vary, from using
50+ 8× N variables (111–113) to 10 participants per predictor
variable (114). Obviously, a larger sample size would always be
advisable. Yet, our sample size matches sample sizes in other stud-
ies reporting on preselected minority samples of (relatively) pure
drug users (3). A potential reason could be firstly, that these indi-
viduals are either extremely difficult to motivate, or secondly, that
pure users of drugs are a rarity, at least in our study region. The
difficulty of finding pure CU may also be reflected in population
descriptions over the last 30 years; many studies inferred on the
influence of cannabis use on cognition and mental health risk
without necessarily ensuring that individuals did not also con-
sume other licit and illicit drugs. We thus face the future challenge
to disentangle the impact of a specific drug use or synergetic drug
uses on cognition and mental health (115–117).
Finally, cognitive attenuations related to cannabis use seem
more overt in heavy as compared to moderate or light users (14,
118, 119). A higher frequency of cannabis use in our sample might
have exacerbated the reported cognitive attenuations. Though
definitions for heavy use may vary (118, 119), the frequency of
cannabis use (joints/week) in our sample seems to indicate heavy
use according to a previous report on pure CU (63). To note, our
data point to a negligible influence of frequency of pure cannabis
use (see Materials and Methods).
CONCLUSION
While pure cannabis and alcohol use seem associated with adverse
effects on cognition, other risk factors (e.g., nicotine use) might
also be relevant. Schizotypy, on the other hand, seems unre-
lated to cognitive attenuation. Results stress the importance to
control for additional substance use (and non-excessive use in
particular), whether illicit or licit, when assessing the effect of
schizotypal symptoms and/or cannabis use on cognition. More-
over, heterogeneity of cannabis-related attenuations of specific
cognitive functions may be avoided by controlling for additional
factors potentially influencing the relationship between cannabis,
cognition, and psychosis (-risk).
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